Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Results from a major clinical trial demonstrate that both stenting and surgery are low-risk and similarly effective procedures for treating carotid artery disease.

" "

The results, published today in The Lancetwere announced simultaneously at the European Society of Cardiology Congress 2021.

Stroke is the second largest cause of death worldwide, responsible for over six million deaths each year. A common cause of stroke is carotid artery disease (also known as carotid artery stenosis), where the large blood vessels that supply oxygen to the brain become narrower. Usually, this is due to deposits of fatty material (atherosclerosis) in the arteries which eventually form hardened plaques.

To reduce their risk of having a deadly stroke, patients with carotid artery disease may undergo one of two different procedures to open up the affected artery and improve blood flow to the brain. Carotid artery surgery, also called carotid endarterectomy (CEA), involves surgically removing the plaque, and is more commonly prescribed. Alternatively, the artery may be opened by inserting a catheter with an inflatable balloon tip, and then a stent added to permanently keep the walls open (carotid artery stenting, CAS).

Up to now it has been unclear which of these procedures results in better overall patient outcomes. This includes both the long-term protective effect against strokes, and the risk of an adverse event happening during or immediately after the operation.

To generate robust evidence that could answer this, researchers have coordinated the Asymptomatic Carotid Surgery Trial 2 (ACST-2), the largest trial to date comparing CAS and CEA. The trial, hosted by the Nuffield Department of Population Health at the University of Oxford, enrolled 3,625 participants from 33 countries. Each participant had been diagnosed with carotid artery disease that had not caused  a stroke.

After agreeing to take part in the study, participants were randomly allocated to undergo either CAS or CEA, and followed up for an average of five years. The main outcomes assessed by the trial were adverse events associated with the procedure itself, and the long-term protective effect against strokes.

Key results:

  • There was no significant difference in the risk of adverse, procedure-related events for CAS and CEA. For both treatments, 1% of patients had a disabling stroke or died within 30 days (15 in the CAS group and 18 in the CEA group) and 2% had a non-disabling stroke (48 in the CAS group and 29 in the CEA group).
  • The number of strokes that occurred in the participants over the five-year follow up period was similar for CAS and CEA. Fatal or disabling stroke occurred in 2.5% of patients in each group, and the total number of strokes was 5.3% in the CAS group, and 4.5% in the CEA group.

Principal Investigator for ACST-2 Professor Alison Halliday, Professor of Vascular Surgery in the Nuffield Department of Surgical Sciences, University of Oxford, said: ‘We have shown that, for patients with a severely narrowed carotid artery, stenting and surgery have similar effects on the chances of having a disabling or fatal stroke. The risk from each procedure is about 1%. After that, however, the annual risk over the next five or more years is halved, from 1% down to 0.5% per year.’

Mr Richard Bulbulia, a Consultant Vascular Surgeon, Co-Principal Investigator for ACST-2, and Research Fellow at the Nuffield Department of Population Health, said: ‘Both stenting and surgery are good treatment options, but there may be particular patient factors which favour one approach over another. Until now, it had been unclear if CAS or CEA results in better overall outcomes on the risk of stroke. The evidence from this trial can give doctors confidence in offering the procedure most suited to their patients, knowing that both options are associated with similar very low risks.’

Similar stories

Discovered gene patterns can predict prostate cancer treatment response

Nearly 40,000 men are diagnosed with prostate cancer each year in the UK. Perhaps the most significant clinical challenge today is deciding which type of treatment will work best for different patient groups.

Regent Lee wins top UKRI Future Leaders Fellowship

Dr Regent Lee of the Nuffield Department of Surgical Sciences is one of eight Oxford University academics who have been awarded significant financial funding from the UK Research and Innovation’s (UKRI) Future Leaders Fellowships Scheme.

New issue of JNDS now online

A new issue of the Journal of the Nuffield Department of Surgical Sciences (JNDS) has been published.

New Cochrane evidence highlights uncertainty about the interventions used to prevent and treat loss of smell after COVID-19 infection

Cochrane ENT at the Nuffield Department of Surgical Sciences has published two systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell following COVID-19 infection.

Using artificial intelligence (AI) for safer CT imaging of blood vessels

Congratulations to Dr Regent Lee at the Nuffield Department of Surgical Sciences (NDS) who has been awarded a grant of £246,226 from Heart Research UK for his research project ‘Using artificial intelligence (AI) for safer CT imaging of blood vessels’.

Blog posts

My virtual work experience with NDS and NDORMS

Louise Tan, a Year 12 student from Ballyclare in County Antrim, Northern Ireland, recently attended the joint NDS and NDORMS Virtual Work Experience. In this guest blog, Louise reflects on her experience.

Celebrating women of NDS

To celebrate 100 years since women were admitted as full members of the University and on the occasion of International Women's Day, a group of inspirational women in the Nuffield Department of Surgical Sciences (NDS) reflect on their journeys, their place in Medical Sciences and their vision for the next 100 years.

The life of a research nurse: supporting the Oxford COVID-19 Vaccine Trial

Research nurses in the NHS are playing a crucial role in helping to trial new coronavirus treatments and vaccines. Three NDS research nurses stepped up to help with the fight against this new disease. Here Bhumika Patel shares her experience of working on the Oxford COVID-19 Vaccine Trial.

Why I became a Peer Supporter

The Peer Support Programme was developed in recognition of the essential role students play in supporting and encouraging one another on a day-to-day basis throughout their time at university. NDS’ own Helen Stark discusses her experience of becoming a Peer Supporter.

Racism under the microscope

As Black History Month gets underway in the UK, NDS Athena SWAN Coordinator Emily Hotine puts racism under the microscope.